clinical trial · NCT04633122
A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With Imatinib
Zai Lab (Shanghai) Co., Ltd.·phase2·completed·n = 108
Gastrointestinal Stromal Tumor(GIST)RipretinibSunitinib
brief summary
the primary objective of this study is to assess the efficacy (progression-free survival,PFS) of DCC-2618 (ripretinib, ZL-2307) and sunitinib in patients with advanced gastrointestinal stromal tumors after treatment with imatinib. This study will enroll approximately 98 subjects in around 18 sites in China mainland, and all subjects will be receiving DCC-2618 or Sunitinib in equal chance as treatment.
started
Nov 25, 2020
primary completion
Jul 20, 2022
completion
Jul 20, 2022
last updated
Apr 3, 2026
official title
A Phase 2, Randomized, Multicenter, Open-label Study of DCC-2618 (Ripretinib, ZL-2307 ) vs Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumors After Treatment With Imatinib
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol